Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Alcohol use disorders are among the top causes of the global burden of disease, yet therapeutic interventions are limited. Reduced desire to drink in patients treated with semaglutide has raised interest regarding its potential therapeutic benefits for alcohol use disorders. In this retrospective cohort study of electronic health records of 83,825 patients with obesity, we show that semaglutide compared with other anti-obesity medications is associated with a 50%-56% lower risk for both the incidence and recurrence of alcohol use disorder for a 12-month follow-up period. Consistent reductions were seen for patients stratified by gender, age group, race and in patients with and without type 2 diabetes. Similar findings are replicated in the study population with 598,803 patients with type 2 diabetes. These findings provide evidence of the potential benefit of semaglutide in AUD in real-world populations and call for further randomized clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rehm, J., Mathers, C., Popova, S., Thavorncharoensap, M., Teerawattananon, Y., & Patra, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60746-7 · Cited by 3,870
Evaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646 · cited 1×
“We used new-user design to mitigate prevalent user bias and confounding associated with the drug itself 55,56 .”
Jonas, D. E., Amick, H. R., Feltner, C., Bobashev, G., Thomas, K., Wines, R., Kim, M. M., Shanahan, E., Gass, C. E., Rowe, C. J., et al. (2014) · JAMA · doi:10.1001/jama.2014.3628 · Cited by 923 · cited 1×
“Despite its large public health impact, there are only 3 medications for AUD approved by the FDA and 4 by the European Medicines Agency (EMA) and their therapeutic bene fi ts are modest 3,4 .”
Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review
Kranzler, H. R., & Soyka, M. (2018) · JAMA · doi:10.1001/jama.2018.11406 · Cited by 580
Alhadeff, A. L., Rupprecht, L. E., & Hayes, M. R. (2012) · Endocrinology · doi:10.1210/en.2011-1443 · Cited by 515 · cited 1×
“…delineated but are likely to involve modulation of the brain dopamine reward system via GLP-1 receptors, which are present both in the ventral tegmental areas (VTA), where dopamine neurons are located, and in the nucleus accumbens (NAc), which is the main projection of VTA dopamine neurons 14 .”
Dickson, S. L., Shirazi, R. H., Hansson, C., Bergquist, F., Nissbrandt, H., & Skibicka, K. P. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.6326-11.2012 · Cited by 414 · cited 1×
“The involvement of the dopamine reward pathway in modulating food and alcohol consumption 15 could explain why semaglutideisbene fi cialinreducingfoodconsumption 16 andinanimal models reducing alcohol and other drug consumption 5 .”
The Addictive Dimensionality of Obesity
Volkow, N. D., Wang, G.-J., Tomasi, D., & Baler, R. D. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.12.020 · Cited by 380 · cited 1×
“Importantly the rewarding effects of food are a main contributor to overeating and obesity 18 just as the rewarding effects of alcohol drive alcohol consumption 19 .”
Self-citationKlausen, M. K., Jensen, M. E., Møller, M., Le Dous, N., Jensen, A.-M. Ø., Zeeman, V. A., Johannsen, C.-F., Lee, A., Thomsen, G. K., Macoveanu, J., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.159863 · Cited by 262 · cited 4×
“…trial study of the GLP-1RA drug exenatide, which signi fi cantly reduced heavy drinking days and total alcohol intake in patients with obesity 12 and with a register-based study in Demark showing that GLP-1RAs (though semaglutide was not included) compared with dipeptidyl peptidase 4…”
InfluentialSelf-citationThe role of glucagon‐like peptide 1 (GLP‐1) in addictive disorders
Klausen, M. K., Thomsen, M., Wortwein, G., & Fink‐Jensen, A. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15677 · Cited by 259 · cited 2×
“Recent reports of reduced drinking in people being treated with glucagon-like peptide-1 receptor agonist (GLP-1RA) medications for T2DM or obesity have generated interest in the potential of these medications for treating AUD 5,6 .”
Association of semaglutide with risk of suicidal ideation in a real-world cohort
Wang, W., Volkow, N. D., Berger, N. A., Davis, P. B., Kaelber, D. C., & Xu, R. (2024) · Nature Medicine · doi:10.1038/s41591-023-02672-2 · Cited by 248 · cited 3×
“We also used the TriNetX platform to examine the associationsofGLP-1RAswithcolorectalcancer 50 andsemaglutidewith suicidal ideations 36 and cannabis use disorder 51 .”
Self-citation
Cited by
Mapping the effectiveness and risks of GLP-1 receptor agonists
Xie, Y., Choi, T., & Al-Aly, Z. (2025) · Nature Medicine · doi:10.1038/s41591-024-03412-w · Cited by 300
Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial
Hendershot, C. S., Bremmer, M. P., Paladino, M. B., Kostantinis, G., Gilmore, T. A., Sullivan, N. R., Tow, A. C., Dermody, S. S., Prince, M. A., Jordan, R., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2024.4789 · Cited by 287
Wang, W., Wang, Q., Qi, X., Gurney, M., Perry, G., Volkow, N. D., Davis, P. B., Kaelber, D. C., & Xu, R. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.14313 · Cited by 180
Self-citationProteomic changes upon treatment with semaglutide in individuals with obesity
Maretty, L., Gill, D., Simonsen, L., Soh, K., Zagkos, L., Galanakis, M., Sibbesen, J., Iglesias, M. T., Secher, A., Valkenborg, D., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03355-2 · Cited by 86
“…propensity-score-matched study of 83,825 patients with obesity, which showed that semaglutide, compared with other non-GLP-1-based obesity medications, was associated with a 50% lower risk for incident and recurrent alcohol use disorders over a 12-month period regardless of T2D status 24 .”
InfluentialWang, W., Volkow, N. D., Berger, N. A., Davis, P. B., Kaelber, D. C., & Xu, R. (2024) · Annals of Internal Medicine · doi:10.7326/m23-2718 · Cited by 72
Self-citation
Metadata
- Authors
- Wang, W., Volkow, N. D., Berger, N. A., Davis, P. B., Kaelber, D. C., & Xu, R.
- Venue
- Nature Communications
- Published
- 2024-05-28
- Volume
- 15
- Issue
- 1
- Pages
- 4548-4548
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W4399113868
- Cited by
- 135
- References
- 14
- FWCI
- 35.30
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. https://app.cochat.ai/papers/10.1038/s41467-024-48780-6
- The paper
- Wang, W., Volkow, N. D., Berger, N. A., Davis, P. B., Kaelber, D. C., & Xu, R. (2024). Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nature Communications. https://doi.org/10.1038/s41467-024-48780-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.